CD71 binding fibronectin type III domains
AssigneeARO Biotherapeutics Company
InventorsRussell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Claims34
A polypeptide comprising the amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 33-39, 41-62, 81-136, 138-186, 188-261, and 263-309, or at least 91% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 40, 137, 187, and 262, or any combination thereof.
A method of delivering an agent of interest to a cluster of differentiation 71 (CD71) positive cell, wherein the method comprises contacting the cell with a conjugate comprising the agent of interest coupled to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 33-62 and 81-309.
Dependencies are inferred from the claim text.